Clinical trials
Completed Ataxia trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
75 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 2 |
| 2003 | 1 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 3 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 4 |
| 2015 | 4 |
| 2016 | 4 |
| 2017 | 3 |
| 2018 | 9 |
| 2019 | 2 |
| 2020 | 5 |
| 2021 | 7 |
| 2022 | 6 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 5 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 75 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hacettepe University | 6 |
| Columbia University | 4 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 4 |
| Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 2 |
| Cairo University | 2 |
| GlaxoSmithKline | 2 |
| Hasan Kalyoncu University | 2 |
| Johns Hopkins University | 2 |
| National Pediatric Neuroinflammation Organization, Inc. | 2 |
| Neuren Pharmaceuticals Limited | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ataxia | 75 |
| Cerebellar Ataxia | 11 |
| Spinocerebellar Ataxias | 9 |
| Spinocerebellar Degenerations | 6 |
| Friedreich Ataxia | 5 |
| Multiple Sclerosis | 5 |
| Constipation | 4 |
| Muscle Weakness | 4 |
| Stroke | 4 |
| Ataxia Telangiectasia | 3 |
Trials
Showing 26 to 50 of 75. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.